VivoSim Labs, Inc. Common Stock
Symbol: VIVS (NASDAQ)
2.48
▲ (32.35%) 0.605
Company Description:
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
Key Stats
- Today's Open: $1.831
- Today's High: $2.937
- Today's Low: $1.8
- Today's Volume: 12.81M
- Yesterday Close: $1.87
- Yesterday High: $1.98
- Yesterday Low: $1.84
- Yesterday Volume: 10.35K
- Last Min Volume: 0
- Last Min High: $2.475
- Last Min Low: $2.472
- Last Min VWAP: $0
Company Profile
- Name: VivoSim Labs, Inc. Common Stock
- Website: https://www.organovo.com
- Listed Date: 2011-08-16
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001497253
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $4.86M
- Round Lot: 100
- Outstanding Shares: 2.60M
- Asset Type: CS
RECENT FILINGS FOR VIVS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-28 | S-8 | View |
| 2025-08-21 | 4 | View |
| 2025-08-21 | 3 | View |
| 2025-08-14 | 8-K | View |
| 2025-08-12 | 10-Q | View |
| 2025-07-29 | 10-K/A | View |
| 2025-06-05 | 10-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-06 | 8-K | View |
| 2025-04-24 | 8-K | View |
| 2025-04-23 | 8-K | View |
| 2025-04-11 | 424B5 | View |
| 2025-04-02 | 8-K | View |
| 2025-03-27 | 8-K | View |
| 2025-03-26 | 8-K | View |
| 2025-03-21 | 8-K | View |
| 2025-03-19 | 8-K | View |
| 2025-03-06 | 8-K | View |
| 2025-02-26 | 424B5 | View |
| 2025-02-25 | 8-K | View |